ES2402220T3 - Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos - Google Patents
Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos Download PDFInfo
- Publication number
- ES2402220T3 ES2402220T3 ES07864160T ES07864160T ES2402220T3 ES 2402220 T3 ES2402220 T3 ES 2402220T3 ES 07864160 T ES07864160 T ES 07864160T ES 07864160 T ES07864160 T ES 07864160T ES 2402220 T3 ES2402220 T3 ES 2402220T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- isoquinolin
- isobutyl
- pyrido
- dimethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86494406P | 2006-11-08 | 2006-11-08 | |
| US864944P | 2006-11-08 | ||
| PCT/US2007/084176 WO2008058261A1 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2402220T3 true ES2402220T3 (es) | 2013-04-29 |
| ES2402220T8 ES2402220T8 (es) | 2021-12-23 |
Family
ID=39110526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07864160T Active ES2402220T3 (es) | 2006-11-08 | 2007-11-08 | Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8039627B2 (enExample) |
| EP (1) | EP2081929B1 (enExample) |
| JP (1) | JP5290185B2 (enExample) |
| KR (1) | KR101500766B1 (enExample) |
| CN (1) | CN101553487B (enExample) |
| AU (1) | AU2007317242B2 (enExample) |
| BR (1) | BRPI0718247B1 (enExample) |
| CA (1) | CA2668689C (enExample) |
| DK (1) | DK2081929T3 (enExample) |
| EA (1) | EA018378B1 (enExample) |
| ES (1) | ES2402220T3 (enExample) |
| IL (1) | IL198250A0 (enExample) |
| MX (1) | MX2009004910A (enExample) |
| PL (1) | PL2081929T3 (enExample) |
| PT (1) | PT2081929E (enExample) |
| WO (1) | WO2008058261A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| WO2011153157A2 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012000308A1 (zh) * | 2010-06-29 | 2012-01-05 | 中国药科大学 | 丁苯那嗪的拆分方法 |
| US8351329B2 (en) * | 2010-09-14 | 2013-01-08 | Cisco Technology, Inc. | Universal load-balancing tunnel encapsulation |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| EP2897615A4 (en) | 2012-09-18 | 2016-04-27 | Auspex Pharmaceuticals Inc | PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20160068526A1 (en) | 2013-01-31 | 2016-03-10 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2015048370A1 (en) * | 2013-09-27 | 2015-04-02 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| EP3424504A1 (en) * | 2013-12-03 | 2019-01-09 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| MX2016009817A (es) * | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| WO2015120110A2 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| WO2015120317A1 (en) | 2014-02-07 | 2015-08-13 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| KR20240011255A (ko) * | 2014-05-06 | 2024-01-25 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 |
| CN107438606B (zh) * | 2015-02-06 | 2020-09-18 | 纽罗克里生物科学有限公司 | [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法 |
| WO2016144901A1 (en) | 2015-03-06 | 2016-09-15 | Auspex Pharmaceuticals, Inc. | Methods for the treatment of abnormal involuntary movement disorders |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| MX390795B (es) * | 2015-06-23 | 2025-03-21 | Neurocrine Biosciences Inc | Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos. |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| WO2017060870A1 (en) | 2015-10-09 | 2017-04-13 | Hermann Russ | Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease |
| CN115304596A (zh) * | 2015-10-30 | 2022-11-08 | 纽罗克里生物科学有限公司 | Valbenazine盐及其多晶形物 |
| SI3394057T1 (sl) | 2015-12-23 | 2022-06-30 | Neurocrine Biosciences, Inc. | Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
| WO2017182916A1 (en) * | 2016-04-22 | 2017-10-26 | Lupin Limited | Novel process for preparation of tetrabenazine and deutetrabenazine |
| US10442800B2 (en) * | 2016-06-29 | 2019-10-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of NBI-98854, preparation method and use thereof |
| WO2018067945A1 (en) * | 2016-10-06 | 2018-04-12 | Assia Chemical Industries Ltd. | Solid state forms of valbenazine |
| WO2018102673A1 (en) | 2016-12-02 | 2018-06-07 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| WO2018130345A1 (en) | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
| MY199695A (en) * | 2017-01-27 | 2023-11-18 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2018153632A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| KR20230003308A (ko) | 2017-03-15 | 2023-01-05 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진의 유사체, 이의 제조 및 용도 |
| GB201705303D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| CN110691596A (zh) * | 2017-04-01 | 2020-01-14 | 阿德普蒂奥制药有限公司 | 药物组合物 |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| DK3684333T3 (da) | 2017-09-21 | 2025-05-12 | Neurocrine Biosciences Inc | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| RU2020114598A (ru) | 2017-11-08 | 2021-12-09 | Фореси Фармасьютикалс Ко., Лтд. | Сложные эфиры дигидротетрабеназина |
| US11384077B2 (en) | 2017-11-22 | 2022-07-12 | Assia Chemical Industries Ltd. | Solid state form of Valbenazine |
| JP7212958B2 (ja) | 2017-12-26 | 2023-01-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | バルベナジントシル酸塩の結晶形及びその製造方法並びに用途 |
| CN110092785A (zh) * | 2018-01-31 | 2019-08-06 | 广东东阳光药业有限公司 | 一种丁苯那嗪的动态拆分方法 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| BR112021000019A2 (pt) | 2018-08-15 | 2021-04-06 | Neurocrine Biosciences Inc. | Métodos para administração de certos inibidores de vmat2 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| EP3860599B1 (en) | 2018-10-04 | 2024-05-15 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| CA3065236A1 (en) | 2018-12-27 | 2020-06-27 | Apotex Inc. | Novel crystalline form of valbenazine dibesylate |
| WO2020213014A1 (en) | 2019-04-19 | 2020-10-22 | Mylan Laboratories Limited | An improved process for the preparation of valbenazine and its salts |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| US12565495B2 (en) * | 2019-08-12 | 2026-03-03 | Luye Innomind Pharma Shijiazhuang Co., Ltd. | VMAT2 inhibitor and preparation method therefor and application thereof |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CN117736203A (zh) | 2019-09-13 | 2024-03-22 | 纽罗克里生物科学有限公司 | 用于合成缬苯那嗪的方法 |
| CN110698397A (zh) * | 2019-10-28 | 2020-01-17 | 南京红杉生物科技有限公司 | 丁苯那嗪中间体及其合成方法、应用和合成用中间产物 |
| AR125188A1 (es) | 2021-03-22 | 2023-06-21 | Neurocrine Biosciences Inc | Inhibidores del vmat2 y métodos de uso |
| WO2022232060A1 (en) | 2021-04-26 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for the synthesis of valbenazine |
| EP4362944A1 (en) | 2021-06-30 | 2024-05-08 | Neurocrine Biosciences, Inc. | Valbenazine for use in the add-on treatment of schizophrenia |
| MX2023014977A (es) | 2021-06-30 | 2024-02-09 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral. |
| IL315181A (en) | 2022-03-07 | 2024-10-01 | Neurocrine Biosciences Inc | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| CN119907800A (zh) | 2022-09-21 | 2025-04-29 | 纽罗克里生物科学有限公司 | 六氢-2H-吡啶并[2,1-a]异喹啉VMAT2抑制剂及其使用方法 |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025038938A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of huntington's chorea |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025199234A1 (en) | 2024-03-20 | 2025-09-25 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| US2852518A (en) * | 1957-05-23 | 1958-09-16 | Parke Davis & Co | Di-substituted quinoline compounds |
| WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| EP2698170A1 (en) | 2005-06-29 | 2014-02-19 | The Trustees of Columbia University in the City of New York | Use of DTBZ for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
| GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB0516168D0 (en) | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| EP1855677B1 (en) | 2005-08-06 | 2008-12-03 | Cambridge Laboratories (Ireland) Limited | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
-
2007
- 2007-11-08 EP EP07864160A patent/EP2081929B1/en active Active
- 2007-11-08 AU AU2007317242A patent/AU2007317242B2/en active Active
- 2007-11-08 EA EA200970461A patent/EA018378B1/ru unknown
- 2007-11-08 PT PT78641602T patent/PT2081929E/pt unknown
- 2007-11-08 CA CA2668689A patent/CA2668689C/en active Active
- 2007-11-08 MX MX2009004910A patent/MX2009004910A/es active IP Right Grant
- 2007-11-08 KR KR1020097011731A patent/KR101500766B1/ko active Active
- 2007-11-08 BR BRPI0718247-3A patent/BRPI0718247B1/pt active IP Right Grant
- 2007-11-08 WO PCT/US2007/084176 patent/WO2008058261A1/en not_active Ceased
- 2007-11-08 US US11/937,445 patent/US8039627B2/en active Active
- 2007-11-08 CN CN2007800395790A patent/CN101553487B/zh active Active
- 2007-11-08 DK DK07864160.2T patent/DK2081929T3/da active
- 2007-11-08 JP JP2009536493A patent/JP5290185B2/ja active Active
- 2007-11-08 PL PL07864160T patent/PL2081929T3/pl unknown
- 2007-11-08 ES ES07864160T patent/ES2402220T3/es active Active
-
2009
- 2009-04-21 IL IL198250A patent/IL198250A0/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,709 patent/US8357697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2402220T8 (es) | 2021-12-23 |
| EA018378B1 (ru) | 2013-07-30 |
| BRPI0718247B1 (pt) | 2021-09-21 |
| US8357697B2 (en) | 2013-01-22 |
| BRPI0718247A2 (pt) | 2014-01-07 |
| KR20090079257A (ko) | 2009-07-21 |
| AU2007317242B2 (en) | 2013-08-01 |
| US20120077839A1 (en) | 2012-03-29 |
| CN101553487A (zh) | 2009-10-07 |
| PL2081929T3 (pl) | 2013-06-28 |
| DK2081929T3 (da) | 2013-04-15 |
| EP2081929A1 (en) | 2009-07-29 |
| CN101553487B (zh) | 2012-06-13 |
| US8039627B2 (en) | 2011-10-18 |
| JP2010509366A (ja) | 2010-03-25 |
| KR101500766B9 (ko) | 2024-09-25 |
| CA2668689C (en) | 2015-12-29 |
| CA2668689A1 (en) | 2008-05-15 |
| WO2008058261A1 (en) | 2008-05-15 |
| EP2081929B1 (en) | 2013-01-09 |
| JP5290185B2 (ja) | 2013-09-18 |
| KR101500766B1 (ko) | 2015-03-16 |
| EA200970461A1 (ru) | 2009-12-30 |
| AU2007317242A1 (en) | 2008-05-15 |
| IL198250A0 (en) | 2009-12-24 |
| MX2009004910A (es) | 2009-07-24 |
| PT2081929E (pt) | 2013-04-15 |
| US20080167337A1 (en) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2402220T3 (es) | Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos | |
| AU2008317375B2 (en) | Deuterated darunavir | |
| ES3037872T3 (en) | Deuterated derivatives of ruxolitinib | |
| CA2824599C (en) | Arginase inhibitors and methods of use thereof | |
| CA2715390A1 (en) | Imaging agents for detecting neurological dysfunction | |
| ES2836429T3 (es) | Análogo de dezocina | |
| AU2012381042A1 (en) | Carboline and carbazole based imaging agents for detecting neurological dysfunction | |
| CN110139863B (zh) | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 | |
| EP3519393B1 (en) | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors | |
| SK20199A3 (en) | Ether muscarinic antagonists | |
| EP3988098A1 (en) | Heterocyclo alkyl compounds used as ccr2/ccr5 antagonist | |
| JPH07503703A (ja) | （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用 | |
| EA021765B1 (ru) | Производные хиназолиндиона, их получение и их различные терапевтические применения | |
| ES2650139T3 (es) | Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGluR 2/3 | |
| LT4381B (lt) | N-monopakeistų ir n, n'-dipakeistų nesimetrinių ciklinių karbamidų gavimo būdas | |
| CN118302418A (zh) | 一种芳杂环类化合物及其应用 | |
| CN101360742A (zh) | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 | |
| IL324923A (en) | Asymmetric phenylalkylamines | |
| AU2023228096A1 (en) | Histamine h3 receptor antagonist and medical use thereof | |
| ES2710544A1 (es) | Nuevos compuestos de tipo pirazolona para el diagnóstico de alergias a antibióticos betalactámicos |